Methods to measure T-cell responses

Expert Review of Vaccines

Volumn 9, Issue 6, 2010, Pages 595-600

  Plebanski, Magdalena ^a   Katsara, Maria ^b   Sheng, Kuo Ching ^b   Xiang, Sue Dong ^a   Apostolopoulos, Vasso ^b  

^a MONASH UNIVERSITY   (Australia)

^b BURNET INSTITUTE   (Australia)

Author keywords

Antigen delivery; Cellular responses; Cytotoxic T lymphocyte; Cytotoxic T lymphocyte precursor; Immunotherapy; OTI; OTII; Proliferation; T cell; Vaccine

Indexed keywords

INTERLEUKIN 2; OVALBUMIN;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSPOT ASSAY; IMMUNOASSAY; LYMPHOCYTE FUNCTION; NONHUMAN; PRE T LYMPHOCYTE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VACCINATION;

ANIMALS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; HEMATOPOIETIC STEM CELLS; HUMANS; NEOPLASMS; OVALBUMIN; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION;

EID: 77953268608     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.10.53     Document Type: Review

References (46)

1. Plebanski M, Aidoo M, Whittle HC, Hill AV. Precursor frequency analysis of cytotoxic T lymphocytes to pre-erythrocytic antigens of Plasmodium falciparum in West Africa. J. Immunol. 158(6), 2849-2855 (1997).
2. Kuerten S, Nowacki TM, Kleen TO, Asaad RJ, Lehmann PV, Tary- Lehmann M. Dissociated production of perforin, granzyme B, and IFN-g by HIV-specific CD8+ cells in HIV infection. AIDS Res. Hum. Retroviruses 24(1), 62-71 (2008).
3. Swiniarski H, Sturmhoefel K, Lee K, Wolf SF, Dorner AJ, O'Toole M. A CTL assay requiring only 150 microliter of mouse blood. J. Immunol. Methods 233(1-2), 1-11 (2000).
4. van Baalen CA, Gruters RA, Berkhoff EG, Osterhaus AD, Rimmelzwaan GF. FATT-CTL assay for detection of antigen-specific cell-mediated cytotoxicity. Cytometry A 73(11), 1058-1065 (2008).
5. Kranz DM, Pasternack MS, Eisen HN. Recognition and lysis of target cells by cytotoxic T lymphocytes. Fed. Proc. 46(2), 309-312 (1987).
6. Moffat JM, Gebhardt T, Doherty PC, Turner SJ, Mintern JD. Granzyme A expression reveals distinct cytolytic CTL subsets following influenza A virus infection. Eur. J. Immunol. 39(5), 1203-1210 (2009).
7. Taffs R, Sitkovsky M, Takayama H. Granule enzyme exocytosis assay for cytotoxic T lymphocyte activation. Curr. Protoc. Immunol. 3(3), 16 (2001).
8. Vanhoutte VJ, McAulay KA, McCarrell E, Turner M, Crawford DH, Haque T. Cytolytic mechanisms and T-cell receptor Vbeta usage by ex vivo generated Epstein-Barr virus-specific cytotoxic T lymphocytes. Immunology 127(4), 577-586 (2009).
9. Ewen C, Kane KP, Shostak I et al. A novel cytotoxicity assay to evaluate antigen-specific CTL responses using a colorimetric substrate for granzyme B. J. Immunol. Methods 276(1-2), 89-101 (2003).
10. Wonderlich J, Shearer G, Livingstone A, Brooks A. Induction and measurement of cytotoxic T lymphocyte activity. Curr. Protoc. Immunol. 3(3), 11 (2006).
11. Jerome KR, Sloan DD, Aubert M. Measurement of CTL-induced cytotoxicity: the caspase 3 assay. Apoptosis 8(6), 563-571 (2003).
12. Valentovic MA, Ball JG. 2-aminophenol and 4-aminophenol toxicity in renal slices from Sprague-Dawley and Fischer 344 rats. J. Toxicol. Environ. Health A 55(3), 225-240 (1998).
13. Kendig DM, Tarloff JB. Inactivation of lactate dehydrogenase by several chemicals: implications for in vitro toxicology studies. Toxicol. In Vitro 21(1), 125-132 (2007).
14. Mishra D, Mishra PK, Dubey V, Nahar M, Dabadghao S, Jain NK. Systemic and mucosal immune response induced by transcutaneous immunization using hepatitis B surface antigen-loaded modified liposomes. Eur. J. Pharm. Sci. 33(4-5), 424-433 (2008).
15. Tough DF, Sprent J, Stephens GL. Measurement of T and B cell turnover with bromodeoxyuridine. Curr. Protoc. Immunol. Chapter 4, Unit 4.7 (2007).
16. Pietersz GA, Li W, Popovski V, Caruana JA, Apostolopoulos V, McKenzie IF. Parameters for using mannan-MUC1 fusion protein to induce cellular immunity. Cancer Immunol. Immunother. 45(6), 321-326 (1998).
17. Li M, Davey GM, Sutherland RM et al. Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo. J. Immunol. 166(10), 6099-6103 (2001).
18. Sheng KC, Kalkanidis M, Pouniotis DS et al. Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity in vitro and in vivo. Eur. J. Immunol. 38(2), 424-436 (2008).
19. Parish CR, Glidden MH, Quah BJ, Warren HS. Use of the intracellular fluorescent dye CFSE to monitor lymphocyte migration and proliferation. Curr. Protoc. Immunol. 4(4), 9 (2009).
20. Quah BJ, Warren HS, Parish CR. Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester. Nat. Protoc. 2(9), 2049-2056 (2007).
21. Apostolopoulos V, Pietersz GA, Loveland BE, Sandrin MS, McKenzie IF. Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses. Proc. Natl Acad. Sci. USA 92(22), 10128-10132 (1995).
22. Apostolopoulos V, Pietersz GA, McKenzie IF. Cell-mediated immune responses to MUC1 fusion protein coupled to mannan. Vaccine 14(9), 930-938 (1996).
23. Lofthouse SA, Apostolopoulos V, Pietersz GA, Li W, McKenzie IF. Induction of T1 (cytotoxic lymphocyte) and/or T2 (antibody) responses to a mucin-1 tumour antigen. Vaccine 15(14), 1586-1593 (1997).
24. Fifis T, Gamvrellis A, Crimeen-Irwin B et al. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J. Immunol. 173(5), 3148-3154 (2004).
25. Xiang SD, Scalzo-Inguanti K, Minigo G, Park A, Hardy CL, Plebanski M. Promising particle-based vaccines in cancer therapy. Expert Rev. Vaccines 7(7), 1103-1119 (2008).
26. Xiang SD, Scholzen A, Minigo G et al. Pathogen recognition and development of particulate vaccines: does size matter? Methods 40(1), 1-9 (2006).
27. Apostolopoulos V, Lofthouse SA, Popovski V, Chelvanayagam G, Sandrin MS, McKenzie IF. Peptide mimics of a tumor antigen induce functional cytotoxic T cells. Nat. Biotechnol. 16(3), 276-280 (1998).
28. Apostolopoulos V, McKenzie IF, Lees C, Matthaei KI, Young IG. A role for IL-5 in the induction of cytotoxic T lymphocytes in vivo. Eur. J. Immunol. 30(6), 1733-1739 (2000).
29. Apostolopoulos V, Osinski C, McKenzie IF. MUC1 cross-reactive Gal a(1,3)Gal antibodies in humans switch immune responses from cellular to humoral. Nat. Med. 4(3), 315-320 (1998).
30. Lees CJ, Apostolopoulos V, Acres B, Ong CS, Popovski V, McKenzie IF. The effect of T1 and T2 cytokines on the cytotoxic T cell response to mannan- MUC1. Cancer Immunol. Immunother. 48(11), 644-652 (2000).
31. Lees CJ, Apostolopoulos V, Acres B et al. Immunotherapy with mannan-MUC1 and IL-12 in MUC1 transgenic mice. Vaccine 19(2-3), 158-162 (2000).
32. Lees CJ, Apostolopoulos V, McKenzie IF. Cytokine production from murine CD4 and CD8 cells after mannan-MUC1 immunization. J. Interferon Cytokine Res. 19(12), 1373-1379 (1999).
33. McKenzie IF, Apostolopoulos V, Lees C et al. Oxidised mannan antigen conjugates preferentially stimulate T1 type immune responses. Vet. Immunol. Immunopathol. 63(1-2), 185-190 (1998).
34. Dooms H, Kahn E, Knoechel B, Abbas AK. IL-2 induces a competitive survival advantage in T lymphocytes. J. Immunol. 172(10), 5973-5979 (2004).
35. Saparov A, Wagner FH, Zheng R et al. Interleukin-2 expression by a subpopulation of primary T cells is linked to enhanced memory/effector function. Immunity 11(3), 271-280 (1999).
36. Kovacs JA, Lempicki RA, Sidorov IA et al. Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. J. Clin. Invest. 115(8), 2139-2148 (2005).
37. Kondrack RM, Harbertson J, Tan JT, McBreen ME, Surh CD, Bradley LM. Interleukin 7 regulates the survival and generation of memory CD4 cells. J. Exp. Med. 198(12), 1797 - 1806 (2003).
38. Picker LJ, Reed-Inderbitzin EF, Hagen SI et al. IL-15 induces CD4 effector memory T cell production and tissue emigration in nonhuman primates. J. Clin. Invest. 116(6), 1514-1524 (2006).
39. Lori F, Weiner DB, Calarota SA, Kelly LM, Lisziewicz J. Cytokine-adjuvanted HIV-DNA vaccination strategies. Springer Semin. Immunopathol. 28(3), 231-238 (2006).
40. Sun P, Schwenk R, White K et al. Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-g. J. Immunol. 171(12), 6961-6967 (2003).
41. Keating SM, Bejon P, Berthoud T et al. Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria. J. Immunol. 175(9), 5675-5680 (2005).
42. Reece WH, Pinder M, Gothard PK et al. A CD4+ T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat. Med. 10(4), 406-410 (2004).
43. Plebanski M, Gilbert SC, Gupta S et al. Association of malaria parasite population structure, HLA, and immunological antagonism. Science 279(5354), 1173-1177 (1998).
44. Plebanski M. Chapter I. Preparation of lymphocytes and identification of lymphocyte sub-populations. In: Lymphocytes - A Practical Approach. McMichael AJ (Ed.). IRL Press, Oxford, UK, 1-26 (1999)
45. Flanagan KL, Plebanski M, Akinwunmi P et al. Broadly distributed T cell reactivity, with no immunodominant loci, to the pre-erythrocytic antigen thrombospondin-related adhesive protein of Plasmodium falciparum in West Africans. Eur. J. Immunol. 29(6), 1943-1954 (1999).
46. Flanagan KL, Plebanski M, Odhiambo K et al. Cellular reactivity to the P. falciparum protein trap in adult kenyans: novel epitopes, complex cytokine patterns, and the impact of natural antigenic variation. Am. J. Trop. Med. Hygiene 74(3), 367-375 (2006).